CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback